CFAO Healthcare renews its strategic partnership with Sanofi in sub-Saharan Africa through Eurapharma
Sèvres, 27 October 2021 – Eurapharma (CFAO Healthcare), the leading distributor of pharmaceutical products and services in Africa and French overseas territories, recently signed an exclusive partnership agreement with Sanofi, a key player in the African healthcare market.
The initiative builds on existing collaborations between the two companies, especially in Africa. It makes Eurapharma Sanofi’s exclusive partner for the distribution and marketing of medicines and vaccines in 25 English- and French-speaking countries across sub-Saharan Africa via E.P. DIS, effective as of 1 October 2021.
Eurapharma supplies medicines and vaccines in 23 African countries, drawing on more than half a century of experience. With an extensive distribution network and effective logistics platform, the company has become the go-to partner for leading pharmaceutical firms seeking to develop their business in Africa and French overseas territories.
“We are delighted to renew and expand our partnership with Sanofi in sub-Saharan Africa. Our commitment to quality and availability is underpinned by the expertise of our teams and more than 70 years’ experience in pharmaceutical logistics,” said Jean-Marc Leccia, Chairman and CEO of Eurapharma.
The two partners share the same vision and goals in ensuring long-term distribution and promotion of medicines and vaccines on the continent. Jon Fairest, Head of Trade & Revenue General Medicines at Sanofi: “We are committed to ensuring as many people as possible have ongoing access to Sanofi medicines and vaccines in sub-Saharan Africa. We have every faith in the ability of E.P. DIS to develop the portfolio of Sanofi medicines and vaccines while also handling commercial and scientific operations in the region through an ethical, integrated service offering that makes therapeutic solutions available to patients and the medical community.”
Eurapharma and Sanofi joined forces to ensure a smooth, gradual transition and implement the new organisation, which has been operational since 1 October 2021. The initiative will not change the way the medical community or patients gain access to Sanofi medicines and vaccines, which E.P. DIS will continue to provide.
See also
